glycolipid hypervirulent tuberculosis strains inhibits innate immune response
fifty million new infections mycobacterium tuberculosis occur annually claiming million lives tuberculosis worldwide despite apparent lack significant genetic heterogeneity strains m tuberculosis mounting evidence considerable heterogeneity exists molecules important disease pathogenesis differences may manifest ability isolates modify host cellular immune response thereby contributing observed diversity clinical outcomes- describe identification functional relevance highly biologically active lipid species polyketide synthase-derived phenolic glycolipid pgl produced subset m tuberculosis isolates belonging w-beijing family show hyperlethality murine disease models disruption pgl synthesis results loss hypervirulent phenotype without significantly affecting bacterial load disease loss pgl found correlate increase release pro-inflammatory cytokines tumour-necrosis factor-alpha interleukins vitro furthermore overproduction pgl m tuberculosis addition purified pgl monocyte-derived macrophages found inhibit release pro-inflammatory mediators dose-dependent manner
